Second Study on Blood Test for FM


In conclusion the aberrant responses to levels of large number of cytokines of vitrostimulated PBMC using the methodology in this study is significantly correlated with the clinical diagnosis of FM. This methodology provides a useful confirmation of the clinical diagnosis of FM. It also reportedly offers a useful tool in analyzing specific responses to therapeutic modalities and medications in order to determine the efficacy of such interventions.

At the October 2013 American College of Rheumatology meeting in San Diego, an abstract podium presentation was made by rheumatologist Dr. Daniel Wallace regarding a new FM/a research study: A Cytokine/Chemokine Multiplex Assay that Is Sensitive and Specific for Fibromyalgia Compared to Controls, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. This study was jointly conducted at Cedars-Sinai Medical Center in Los Angeles and at the University of Illinois College of Medicine at Chicago.

The clinical diagnosis of FM has been based on subjective evaluations paired with the exclusion of other diseases. No confirmatory objective laboratory benchmark has been available. To investigate potential FM biomarkers, the researchers previously determined whether blood mononuclear cell (PBMC) cytokine/chemokine responses to mitogenic cytokine/chemokine production is altered in FM patients by comparing their in vitro peripheral cytokine/chemokine activators with matched healthy controls. A multiplex immunoassay (Luminex™) was used on PBMC supernatants. Based on a larger multiplex array exploratory pilot study, a custom panel of antibody conjugated beads for eight cytokines/chemokines was used. This panel was 93% sensitive for the diagnosis of FM. The current study was designed to address the specificity of the panel for FM vs SLE and RA.

A total of 25 SLE and 25 RA patients, fulfilling ACR criteria, were recruited and compared with 101 FM patients and 91 controls. Peripheral blood was harvested and PBMC isolated by differential centrifugation on Ficoll. These cells were cultured overnight in medium alone or in the presence of mitogenic activators; PHA or PMA in combination with ionomycin. The supernatant cytokine/chemokine concentrations were determined using the Luminex multiplex immunoassay bead array technology. Data was ported to "R" statistical software for appropriate analysis. The standard curve was fitted with a 5-PL model and the concentrations of the analytes were quantified according to this curve. The two sided t-test was used to test whether the mean concentrations of each chemokine and cytokine were the same in every group. Each patient's profile was scored, as previously described, and ported to statistical software for appropriate analysis.

Compared to FM, cytokine/chemokine levels from stimulated RA and SLE PBMC supernatants were significantly different (p_0.002). The concentrations of all cytokines except for IL-8 in RA were significantly lower in FM than in SLE or RA at 1% false discovery rate. In SLE and RA, 68% and 76%, respectively, tested negative for the FM profile. This was lower than healthy controls at 89%. Concomitant corticosteroid use might explain this since in steroid naive SLE and RA, the negative FM profile increased to 86% and 83%, respectively. There was no statistically significant difference at the 95% confidence level between the concentrations of chemokines and cytokines in SLE and RA patients except for MIP-1b (p_0.042), which was
higher in the SLE cohort.

These data demonstrate that lowered cytokine/chemokine profiles from stimulated PBMC may represent a biomarker that is relatively sensitive and specific for FM compared to SLE and RA. It remains unclear if these differences are directly related to the pathogenesis of FM or if subsequent measurements will be useful in longitudinal outcome studies. This test may represent the first objective laboratory marker for an otherwise enigmatic and clinically defined rheumatic disease.

The bottom line is that the test identified FM separate from Lupus or RA and was 97% specific to fibromyalgia. The NFMCPA will keep you apprised of further information regarding this test as it becomes available.